BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16759855)

  • 21. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
    Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
    Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
    J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureas.
    Jin J; Wang Y; Shi D; Wang F; Fu W; Davis RS; Jin Q; Foley JJ; Sarau HM; Morrow DM; Moore ML; Rivero RA; Palovich M; Salmon M; Belmonte KE; Busch-Petersen J
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5481-6. PubMed ID: 18818072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Mastalerz H; Chang M; Chen P; Dextraze P; Fink BE; Gavai A; Goyal B; Han WC; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Ruediger E; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2036-42. PubMed ID: 17270437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.
    Evans KA; Li YH; Coppo FT; Graybill TL; Cichy-Knight M; Patel M; Gale J; Li H; Thrall SH; Tew D; Tavares F; Thomson SA; Weiel JE; Boucheron JA; Clancy DC; Epperly AH; Golden PL
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4068-71. PubMed ID: 18554908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase.
    Anandan SK; Webb HK; Do ZN; Gless RD
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4259-63. PubMed ID: 19520575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
    Ho CY; Ludovici DW; Maharoof US; Mei J; Sechler JL; Tuman RW; Strobel ED; Andraka L; Yen HK; Leo G; Li J; Almond H; Lu H; DeVine A; Tominovich RM; Baker J; Emanuel S; Gruninger RH; Middleton SA; Johnson DL; Galemmo RA
    J Med Chem; 2005 Dec; 48(26):8163-73. PubMed ID: 16366598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies.
    Tong Y; Claiborne A; Pyzytulinska M; Tao ZF; Stewart KD; Kovar P; Chen Z; Credo RB; Guan R; Merta PJ; Zhang H; Bouska J; Everitt EA; Murry BP; Hickman D; Stratton TJ; Wu J; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3618-23. PubMed ID: 17490879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
    Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
    Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
    Cozza G; Gianoncelli A; Montopoli M; Caparrotta L; Venerando A; Meggio F; Pinna LA; Zagotto G; Moro S
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5672-5. PubMed ID: 18799313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
    Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
    Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-C-glycosiduronic acids and beta-C-glycosyl compounds: new PTP1B inhibitors.
    Lin L; Shen Q; Chen GR; Xie J
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6348-51. PubMed ID: 18993066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton.
    Yamatsugu K; Motoki R; Kanai M; Shibasaki M
    Chem Asian J; 2006 Sep; 1(3):314-21. PubMed ID: 17441066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design of PDK1 inhibitors.
    Poulsen A; Blanchard S; Soh CK; Lee C; Williams M; Wang H; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(1):305-7. PubMed ID: 22119465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.